{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:39:37Z","timestamp":1771922377375,"version":"3.50.1"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2026.1778439","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:32:04Z","timestamp":1768545124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Thymus biology: development, immunodeficiency and cancer progression"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongfeng","family":"He","sequence":"first","affiliation":[{"name":"Department of Cardiothoracic Surgery, Weill Cornell Medicine","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute of Cellular Therapeutics, Allegheny Health Network","place":["Pittsburgh, PA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolai Stanislas","family":"van Oers","sequence":"additional","affiliation":[{"name":"Department of Immunology, University of Texas Southwestern Medical Center","place":["Dallas, TX, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.059998","article-title":"Mechanisms of thymus organogenesis and morphogenesis","volume":"138","author":"Gordon","year":"2011","journal-title":"Development"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127565","article-title":"FOXN1 compound heterozygous mutations cause selective thymic hypoplasia in humans","volume":"129","author":"Du","year":"2019","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-043794","article-title":"Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging","volume":"109","author":"Min","year":"2007","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01583-3","article-title":"De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids","volume":"19","author":"Zeleniak","year":"2022","journal-title":"Nat Methods"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/13543784.2022.2113373","article-title":"Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials","volume":"31","author":"Conforti","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100392","DOI":"10.1016\/j.xcrm.2021.100392","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1556-086402905-3","DOI":"10.1016\/j.jtho.2025.11.011","article-title":"Longitudinal genomic analysis of five cases of recurrent thymomas","volume":"20","author":"He","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:34:48Z","timestamp":1771918488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1778439"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1778439","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1778439"}}